Cargando…

Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial

This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide (UMIN-CTR Cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Todo, Tomoki, Ito, Hirotaka, Ino, Yasushi, Ohtsu, Hiroshi, Ota, Yasunori, Shibahara, Junji, Tanaka, Minoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388376/ https://www.ncbi.nlm.nih.gov/pubmed/35864254 http://dx.doi.org/10.1038/s41591-022-01897-x

Ejemplares similares

A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma
por: Todo, Tomoki, et al.
Publicado: (2022)

Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation
por: Sugawara, Kotaro, et al.
Publicado: (2021)

Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models
por: Inoue, Kosuke, et al.
Publicado: (2023)

Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis
por: Uchihashi, Toshihiro, et al.
Publicado: (2021)

Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma
por: Yajima, Shoh, et al.
Publicado: (2021)

Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer
por: Sugawara, Kotaro, et al.
Publicado: (2020)

Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation
por: Yamada, Tomoharu, et al.
Publicado: (2020)

Third‐generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice
por: Nakatake, Richi, et al.
Publicado: (2018)

Oncolytic virus therapy: A new era of cancer treatment at dawn
por: Fukuhara, Hiroshi, et al.
Publicado: (2016)

Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma
por: Chalise, Lushun, et al.
Publicado: (2022)

Triple‐mutated oncolytic herpes virus for treating both fast‐ and slow‐growing tumors
por: Fukuhara, Hiroshi, et al.
Publicado: (2021)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12
por: Fukuhara, Hiroshi, et al.
Publicado: (2023)

Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models
por: Matsushima, Hideyuki, et al.
Publicado: (2019)

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta
por: Wang, Jiani, et al.
Publicado: (2014)

Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer
por: Matsumura, Shuichi, et al.
Publicado: (2021)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer
por: Kato, Tomoya, et al.
Publicado: (2021)

Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer
por: Kato, Tomoya, et al.
Publicado: (2021)

Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma
por: Chen, Lishu, et al.
Publicado: (2022)

Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models
por: Hatta, Masahiko, et al.
Publicado: (2022)

Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma
por: Wang, Jia-Ni, et al.
Publicado: (2011)

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy
por: Ning, Jianfang, et al.
Publicado: (2014)

Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells
por: Kardani, Kimia, et al.
Publicado: (2023)

Designing herpes viruses as oncolytics
por: Peters, Cole, et al.
Publicado: (2015)

Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models
por: Koch, Marilin S, et al.
Publicado: (2022)

Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors
por: Yamada, Tomoharu, et al.
Publicado: (2022)

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus
por: Reinhart, Bonnie, et al.
Publicado: (2012)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Discovery of Intratumoral Oncolytic Bacteria Toward Targeted Anticancer Theranostics
por: Goto, Yamato, et al.
Publicado: (2023)

Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and prolongs virus persistence at tumor site
por: Fu, Xinping, et al.
Publicado: (2018)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

MiR-199a Inhibits Secondary Envelopment of Herpes Simplex Virus-1 Through the Downregulation of Cdc42-specific GTPase Activating Protein Localized in Golgi Apparatus
por: Kobayashi, Kyousuke, et al.
Publicado: (2017)

Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
por: Zhang, Bo, et al.
Publicado: (2021)

Systemic CD8(+) T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor
por: Ishihara, Mikiya, et al.
Publicado: (2014)

Unifying models of glioblastoma’s intratumoral heterogeneity
por: Lam, K H Brian, et al.
Publicado: (2020)

An oncolytic herpes virus expressing E-cadherin resists NK cell clearance and improves viral spread and glioblastoma virotherapy
por: Xu, Bo, et al.
Publicado: (2018)

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs
por: Braidwood, Lynne, et al.
Publicado: (2013)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity
por: Zhang, Wen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l2s19aeeehmh5oajpdh8tmkl5v